Home Cart Sign in  
Chemical Structure| 252003-65-9 Chemical Structure| 252003-65-9

Structure of CP-547632
CAS No.: 252003-65-9

Chemical Structure| 252003-65-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CP-547632 is a potent inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases (IC50 11 and 9 nM, respectively). It is selective relative to epidermal growth factor receptor, platelet-derived growth factor, and other related TKs. It also inhibits VEGF-stimulated autophosphorylation of VEGFR-2 in a whole cell assay with an IC50 value of 6 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CP-547632

CAS No. :252003-65-9
Formula : C20H24BrF2N5O3S
M.W : 532.40
SMILES Code : NC(=O)C1=C(NC(=O)NCCCCN2CCCC2)SN=C1OCC1=C(F)C=C(Br)C=C1F
MDL No. :MFCD07772279
InChI Key :HXHAJRMTJXHJJZ-UHFFFAOYSA-N
Pubchem ID :9811611

Safety of CP-547632

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H320-H335
Precautionary Statements:P264-P270-P301+P312-P330

Related Pathways of CP-547632

RTK

Isoform Comparison

Biological Activity

Description
CP-547632 is an orally active, ATP-competitive inhibitor that potently targets VEGFR-2 and FGF kinases, with IC50 values of 11 nM and 9 nM, respectively. It exhibits selectivity for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 demonstrates antitumor efficacy[1].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00074854 Lung Neoplasms Phase 1 Phase 2 Completed - United States, California ... More >> Pfizer Investigational Site Greenbrae, California, United States, 94904 Pfizer Investigational Site San Mateo, California, United States, 94402 Pfizer Investigational Site San Pablo, California, United States, 94806 United States, Florida Pfizer Investigational Site Tampa, Florida, United States, 33612-9497 United States, Louisiana Pfizer Investigational Site Covington, Louisiana, United States, 70433 Pfizer Investigational Site Metairie, Louisiana, United States, 70002 Pfizer Investigational Site Metairie, Louisiana, United States, 70006 Pfizer Investigational Site New Orleans, Louisiana, United States, 70115 United States, Massachusetts Pfizer Investigational Site Boston, Massachusetts, United States, 02215 United States, New York Pfizer Investigational Site Stony Brook, New York, United States, 11794 United States, Pennsylvania Pfizer Investigational Site Philadelphia, Pennsylvania, United States, 19111 United States, Tennessee Pfizer Investigational Site Gallatin, Tennessee, United States, 37066 Pfizer Investigational Site Hermitage, Tennessee, United States, 37076 Pfizer Investigational Site Lebanon, Tennessee, United States, 37087 Pfizer Investigational Site Murfreesboro, Tennessee, United States, 37130 Pfizer Investigational Site Nashville, Tennessee, United States, 37203 Pfizer Investigational Site Nashville, Tennessee, United States, 37205 Pfizer Investigational Site Nashville, Tennessee, United States, 37207 Pfizer Investigational Site Nashville, Tennessee, United States, 37211 Pfizer Investigational Site Smyrna, Tennessee, United States, 37167 Less <<
NCT00096239 Fallopian Tube Cancer ... More >> Ovarian Cancer Primary Peritoneal Cavity Cancer Less << Phase 2 Completed - United States, California ... More >> Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California, United States, 90095-1781 Less <<
NCT00074867 Ovarian Neoplasms ... More >> Peritoneal Neoplasms Fallopian Tube Neoplasms Less << Phase 2 Completed - United States, California ... More >> Pfizer Investigational Site Los Angeles, California, United States, 90095 Pfizer Investigational Site Santa Monica, California, United States, 90404 United States, Maryland Pfizer Investigational Site Baltimore, Maryland, United States, 21237 United States, Massachusetts Pfizer Investigational Site Boston, Massachusetts, United States, 02114 Pfizer Investigational Site Boston, Massachusetts, United States, 02115 Pfizer Investigational Site Boston, Massachusetts, United States, 02215 United States, New York Pfizer Investigational Site New York, New York, United States, 10016 Canada, Ontario Pfizer Investigational Site Hamilton, Ontario, Canada, L8V 5C2 Canada Pfizer Investigational Site Quebec, Canada, G1R 2J6 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.88mL

0.38mL

0.19mL

9.39mL

1.88mL

0.94mL

18.78mL

3.76mL

1.88mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories